Derivation of GMP raw materials for use in regenerative medicine: hESC-based therapies, progress toward clinical
Z A Hewitt1, K J Amps, H D Moore
1Sheffield Stem Cell Derivation Facility, Centre for Stem Cell Biology, University of Sheffield, Sheffield, UK. z.hewitt@sheffield.ac.uk
Abstract:
The potential of somatic cell therapies from human embryonic stem cells (hESCs) as alternatives to traditional drug-based remedies for treating some of mankind's most debilitating diseases has resulted in the need to translate rapidly proof-of-principle and basic research into clinical application. Consequently, researchers and regulatory bodies are now facing one of the major obstacles of the field: the efficient and reproducible generation of clinical-grade cells suitable for producing therapeutic cell types to administer to patients in phase-I and phase-II clinical trials.
Related Concept Videos
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
iPS Cell Differentiation


